WO2010062038A2 - Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same - Google Patents

Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same Download PDF

Info

Publication number
WO2010062038A2
WO2010062038A2 PCT/KR2009/006050 KR2009006050W WO2010062038A2 WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2 KR 2009006050 W KR2009006050 W KR 2009006050W WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2
Authority
WO
WIPO (PCT)
Prior art keywords
isomer
tyrosine kinase
pharmaceutical composition
composition containing
same
Prior art date
Application number
PCT/KR2009/006050
Other languages
French (fr)
Korean (ko)
Other versions
WO2010062038A3 (en
Inventor
양범석
김선영
조종운
이향숙
우성호
박태교
김용주
김승태
이홍범
Original Assignee
한국과학기술연구원
주식회사 레고켐 바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국과학기술연구원, 주식회사 레고켐 바이오사이언스 filed Critical 한국과학기술연구원
Publication of WO2010062038A2 publication Critical patent/WO2010062038A2/en
Publication of WO2010062038A3 publication Critical patent/WO2010062038A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Abstract

The present invention relates to a compound expressed in the following chemical formula 1, to an isomer thereof, or to a pharmaceutically allowable salt thereof. The compound expressed in chemical formula 1 inhibits the tyrosine kinase activity of Discoidin Domain Receptor 1 (DDR1) and Discoidin Domain Receptor 2 (DDR2), and thus can be valuably used in the prevention or treatment of diseases such as a cancer, hepatocirrhosis, arteriosclerosis, rheumatoid arthritis, osteoarthritis, and the like, which are known to be mainly caused by an excessive activation of Discoidin Domain Receptor 1 or Discoidin Domain Receptor 2.
PCT/KR2009/006050 2008-11-27 2009-10-20 Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same WO2010062038A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080118850A KR101126736B1 (en) 2008-11-27 2008-11-27 Tyrosine kinase inhibitory compounds, isomers thereof or pharmaceutical acceptable salts thereof, and pharmaceutical composition comprising the same
KR10-2008-0118850 2008-11-27

Publications (2)

Publication Number Publication Date
WO2010062038A2 true WO2010062038A2 (en) 2010-06-03
WO2010062038A3 WO2010062038A3 (en) 2010-07-22

Family

ID=42226201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006050 WO2010062038A2 (en) 2008-11-27 2009-10-20 Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same

Country Status (2)

Country Link
KR (1) KR101126736B1 (en)
WO (1) WO2010062038A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072482A1 (en) * 2010-05-26 2013-03-21 Beom-Seok Yang Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
CN103087077A (en) * 2011-11-03 2013-05-08 上海希迈医药科技有限公司 Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines
WO2013068836A1 (en) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
JP2013538223A (en) * 2010-09-15 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー Azabenzothiazole compounds, compositions and methods of use
CN103360407A (en) * 2012-04-10 2013-10-23 上海希迈医药科技有限公司 Thiophene miazines derivate as well as preparation method and medical application thereof
JPWO2015060373A1 (en) * 2013-10-23 2017-03-09 中外製薬株式会社 Quinazolinone and isoquinolinone derivatives
WO2018171726A1 (en) * 2017-03-23 2018-09-27 高雄医学大学 Discoidin domain receptor 1 inhibitor and activator and use thereof
WO2021239643A1 (en) 2020-05-25 2021-12-02 Chiesi Farmaceutici S.P.A. Benzylamine derivatives as ddrs inhibitors
EP4032896A1 (en) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2023210599A1 (en) * 2022-04-25 2023-11-02 日本新薬株式会社 Compound serving as ddr1 kinase inhibitor, and medicine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540051B1 (en) * 2013-11-27 2015-07-28 한국과학기술연구원 Composition for preventing skin aging or improving skin condition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
WO1997013771A1 (en) * 1995-10-11 1997-04-17 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
KR20010031908A (en) * 1997-11-11 2001-04-16 실버스타인 아써 에이. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20040019065A1 (en) * 2002-03-01 2004-01-29 Romines William Henry Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
WO1997013771A1 (en) * 1995-10-11 1997-04-17 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
KR20010031908A (en) * 1997-11-11 2001-04-16 실버스타인 아써 에이. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20040019065A1 (en) * 2002-03-01 2004-01-29 Romines William Henry Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072482A1 (en) * 2010-05-26 2013-03-21 Beom-Seok Yang Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
US9062066B2 (en) * 2010-05-26 2015-06-23 Korea Institute Of Science And Technology Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
JP2013538223A (en) * 2010-09-15 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー Azabenzothiazole compounds, compositions and methods of use
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CN103087077B (en) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically
WO2013064068A1 (en) * 2011-11-03 2013-05-10 上海希迈医药科技有限公司 Thienopyrimidine and furopyrimidine derivatives, preparation method thereof and medical use thereof
CN103087077A (en) * 2011-11-03 2013-05-08 上海希迈医药科技有限公司 Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines
WO2013068836A1 (en) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
CN103360407A (en) * 2012-04-10 2013-10-23 上海希迈医药科技有限公司 Thiophene miazines derivate as well as preparation method and medical application thereof
CN103360407B (en) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 A kind of Thienopyrimidine analog derivative, its preparation method and in application pharmaceutically
EP3061749A4 (en) * 2013-10-23 2017-05-31 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
JPWO2015060373A1 (en) * 2013-10-23 2017-03-09 中外製薬株式会社 Quinazolinone and isoquinolinone derivatives
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2018171726A1 (en) * 2017-03-23 2018-09-27 高雄医学大学 Discoidin domain receptor 1 inhibitor and activator and use thereof
US10946021B2 (en) 2017-03-23 2021-03-16 Kaohsiung Medical University Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1)
WO2021239643A1 (en) 2020-05-25 2021-12-02 Chiesi Farmaceutici S.P.A. Benzylamine derivatives as ddrs inhibitors
EP4032896A1 (en) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2022157166A1 (en) 2021-01-20 2022-07-28 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2023210599A1 (en) * 2022-04-25 2023-11-02 日本新薬株式会社 Compound serving as ddr1 kinase inhibitor, and medicine

Also Published As

Publication number Publication date
KR20100060300A (en) 2010-06-07
WO2010062038A3 (en) 2010-07-22
KR101126736B1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2010062038A2 (en) Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2009013077A (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
MX2007015863A (en) Sphingosine kinase inhibitors.
UA94622C2 (en) Kinase innhibitor
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2011052923A3 (en) Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
EP2134346A4 (en) Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
PL1899329T3 (en) Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
WO2008118391A3 (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2012013197A (en) Indazole inhibitors of kinase.
NZ623069A (en) Heat shock protein binding compounds, compositions, and methods for making and using same
WO2008011557A3 (en) Heteroaryl inhibitors of rho kinase
MY148634A (en) Pyridazinone derivatives
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2011013325A (en) 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.08.11 AND 02.09.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2